| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
5,660,000 |
| Market
Cap: |
2.49(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4404 - $0.4404 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Graybug Vision is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Co.'s product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are causes of retinal disease. Co.'s second product candidate, GB-401, is an intravitreally administered, proprietary implant formulation containing a prodrug of a beta-adrenergic receptor inhibitor developed to provide a controlled release of the active drug to maintain reduced intraocular pressure, for six months or longer after a single injection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
4,000 |
1,363,274 |
1,467,615 |
1,505,415 |
| Total Buy Value |
$15,600 |
$5,047,430 |
$5,388,501 |
$5,493,543 |
| Total People Bought |
1 |
4 |
7 |
7 |
| Total Buy Transactions |
2 |
6 |
45 |
58 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bjerkholt Eric |
Director |
– • – |
2023-05-19 |
4 |
B |
$2.65 |
$527 |
D/D |
199 |
2,929 |
2.31 |
- |
|
| Bjerkholt Eric |
Director |
– • – |
2023-05-18 |
4 |
B |
$2.65 |
$3 |
D/D |
1 |
2,730 |
2.31 |
- |
|
| Bjerkholt Eric |
Director |
– • – |
2023-05-18 |
4 |
B |
$2.70 |
$810 |
D/D |
300 |
2,729 |
2.31 |
- |
|
| Bjerkholt Eric |
Director |
– • – |
2023-05-17 |
4 |
B |
$2.67 |
$534 |
D/D |
200 |
2,429 |
2.31 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-05-17 |
4 |
B |
$2.68 |
$8,040 |
D/D |
3,000 |
6,500 |
3.15 |
- |
|
| Leheny A. Rachel |
Chief Executive Officer |
• • • |
2023-05-16 |
4/A |
B |
$2.70 |
$2,698 |
I/I |
1,000 |
1,000 |
2.56 |
- |
|
| Bjerkholt Eric |
Director |
– • – |
2023-05-16 |
4 |
B |
$2.70 |
$2,160 |
D/D |
800 |
2,229 |
2.31 |
- |
|
| Hebbar Sudarshan |
Chief Medical Officer |
• – – |
2023-05-16 |
4 |
B |
$2.70 |
$26,999 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Leheny A. Rachel |
Chief Executive Officer |
• • • |
2023-05-16 |
4 |
B |
$2.69 |
$2,690 |
D/D |
1,000 |
1,000 |
3.15 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-05-16 |
4 |
B |
$2.72 |
$4,896 |
I/I |
1,800 |
1,800 |
2.56 |
- |
|
| Roberts Eric W |
Chief Business Officer |
• • • |
2023-05-16 |
4 |
B |
$2.71 |
$9,485 |
D/D |
3,500 |
3,500 |
3.15 |
- |
|
| Ackermann Christina |
Director |
– • – |
2023-03-23 |
4 |
|
$0.00 |
$0 |
D/D |
1,429 |
1,429 |
|
- |
|
| Bjerkholt Eric |
Director |
– • – |
2023-03-23 |
4 |
|
$0.00 |
$0 |
D/D |
1,429 |
1,429 |
|
- |
|
| Sauer Dirk |
Director |
– • – |
2023-03-23 |
4 |
|
$0.00 |
$0 |
D/D |
1,429 |
1,429 |
|
- |
|
| Zamiri Parisa |
Chief Medical Officer |
• – – |
2023-03-23 |
4 |
D |
$5.50 |
$98,456 |
D/D |
(17,901) |
28,982 |
|
- |
|
| Zamiri Parisa |
Chief Medical Officer |
• – – |
2023-03-23 |
4 |
|
$0.00 |
$0 |
D/D |
42,771 |
46,883 |
|
- |
|
| Guerard Frederic |
Chief Executive Officer |
• • – |
2023-03-23 |
4 |
D |
$5.50 |
$112,107 |
D/D |
(20,383) |
90,727 |
|
- |
|
| Guerard Frederic |
Chief Executive Officer |
• • – |
2023-03-23 |
4 |
|
$0.00 |
$0 |
D/D |
83,705 |
111,110 |
|
- |
|
| Shaffer Christy L |
Director |
– • – |
2023-03-23 |
4 |
|
$0.00 |
$0 |
D/D |
1,429 |
1,429 |
|
- |
|
| Breuil Robert S |
Chief Financial Officer |
• – – |
2023-03-23 |
4 |
D |
$5.50 |
$69,724 |
D/D |
(12,677) |
35,326 |
|
- |
|
| Breuil Robert S |
Chief Financial Officer |
• – – |
2023-03-23 |
4 |
|
$0.00 |
$0 |
D/D |
36,657 |
48,003 |
|
- |
|
| Eastland Julia Marie |
Director |
– • – |
2023-03-23 |
4 |
|
$0.00 |
$0 |
D/D |
1,429 |
1,429 |
|
- |
|
| Sanderling Ventures Vii (canada), L.p. |
10% Owner |
– – • |
2023-03-20 |
4 |
A |
$0.00 |
$0 |
I/I |
936,656 |
1,548 |
|
- |
|
| Sanderling Ventures Vii (canada), L.p. |
10% Owner |
– – • |
2023-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
703,388 |
703,388 |
|
- |
|
| Valence Investments Spv Vi, Llc |
10% Owner |
– – • |
2023-03-20 |
4 |
A |
$0.00 |
$0 |
I/I |
382,337 |
316,109 |
|
- |
|
131 Records found
|
|
Page 3 of 6 |
|
|
